COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR (2002) Lancet 360: 1071-3 Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Hennan JK, Huang J, Barrett TD, Driscoll EM, Willens DE, Park AM, Crofford LJ, Lucchesi BR (2001) Circulation 104: 820-5 Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN (2001) Gastroenterology 120: 1713-9 Opposing roles of LTB4 and PGE2 in regulating the inflammasome-dependent scorpion venom-induced mortality. Zoccal KF, Sorgi CA, Hori JI, Paula-Silva FW, Arantes EC, Serezani CH, Zamboni DS, Faccioli LH (2016) Nat Commun 7: 10760 Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN (2000) Cancer Res 60: 6045-51 A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, Morrow JD, Sandler AB, Shyr Y, Ye F, Choy H (2009) Clin Cancer Res 15: 2158-65 A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA (2006) Clin Cancer Res 12: 3381-8 Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. Crofford LJ, Oates JC, McCune WJ, Gupta S, Kaplan MJ, Catella-Lawson F, Morrow JD, McDonagh KT, Schmaier AH (2000) Arthritis Rheum 43: 1891-6 Are all COX-2 inhibitors created equal? Chang IJ, Harris RC (2005) Hypertension 45: 178-80 A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. Sinsakul M, Sika M, Rodby R, Middleton J, Shyr Y, Chen H, Han E, Lehrich R, Clyne S, Schulman G, Harris R, Lewis J (2007) Am J Kidney Dis 50: 946-51 Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use? Crofford LJ (2002) Curr Opin Rheumatol 14: 225-30 Comparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2 function in female reproduction in mice. Reese J, Zhao X, Ma WG, Brown N, Maziasz TJ, Dey SK (2001) Endocrinology 142: 3198-206 Targeting prostaglandin E2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages. Pavlovic S, Du B, Sakamoto K, Khan KM, Natarajan C, Breyer RM, Dannenberg AJ, Falcone DJ (2006) J Biol Chem 281: 3321-8 Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT. Montine TJ, Sonnen JA, Milne G, Baker LD, Breitner JC (2010) PLoS One 5: e9340 The effects of nepafenac and amfenac on retinal angiogenesis. Yanni SE, Clark ML, Yang R, Bingaman DP, Penn JS (2010) Brain Res Bull 81: 310-9 COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease. Ray WA, MacDonald TM, Solomon DH, Graham DJ, Avorn J (2003) Pharmacoepidemiol Drug Saf 12: 67-70 Dual blockade of the EGFR and COX-2 pathways: a phase II trial of cetuximab and celecoxib in patients with chemotherapy refractory metastatic colorectal cancer. Chan E, Lafleur B, Rothenberg ML, Merchant N, Lockhart AC, Trivedi B, Chung CH, Coffey RJ, Berlin JD (2011) Am J Clin Oncol 34: 581-6
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.